Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

Next Previous
Trial Profile

A Phase 2b Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy Versus Bulevirtide in Participants With Chronic HDV Infection (ECLIPSE 3)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; Tobevibart (Primary) ; Bulevirtide
  • Indications Hepatitis D
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ECLIPSE 3
  • Sponsors Vir Biotechnology

Most Recent Events

  • 06 Aug 2025 According to a Vir Biotechnology media release, this trial ECLIPSE 3 will provide important supportive data to help establish access and reimbursement in key markets.
  • 06 Aug 2025 According to a Vir Biotechnology media release, company announced the enrollment of the first participant in this trial.
  • 24 Jun 2025 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top